Last $1.18 USD
Change Today 0.00 / 0.00%
Volume 14.4K
BSPM On Other Exchanges
As of 1:03 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

biostar pharmaceuticals inc (BSPM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $3.49
52 Week Low
01/30/15 - $0.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

biostar pharmaceuticals inc (BSPM) Related Businessweek News

No Related Businessweek News Found

biostar pharmaceuticals inc (BSPM) Details

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People’s Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for the treatment of chronic hepatitis B. Its current product line also includes 5 other OTC products, 10 prescription-based pharmaceuticals, 6 nutriceuticals or health products, and 1 medical device. The company’s OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat pain, headache, and fever; and Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for the treatment of pain and other symptoms associated with menstruation. Its prescription pharmaceutical products include Danshen granule for the treatment of coronary heart disease, myocarditis, and angina pectoris; and Taohuasan pediatric medicine for the treatment of bronchial congestion and coughs in children. In addition, the company manufactures hernia belt, a medical device used for the relief of hernia. Further, it provides nutrient and OTC products, which comprise Tangning capsule for the treatment of diabetes; Yizi capsule for fertility; Shengjing capsule for kidney; and Aoxing ointment to treat psoriasis, vitiligo, and various dermatitis. Additionally, the company operates, a Website that serves as Internet-based China Hepatitis Internet hospital, which provides HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through 68 distributors and a network of approximately 226 dedicated sales people in approximately 27 provinces. The company is headquartered in Xianyang, the People’s Republic of China.

438 Employees
Last Reported Date: 03/31/14

biostar pharmaceuticals inc (BSPM) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $17.4K
Interim Chief Financial Officer and Director
Total Annual Compensation: $11.0K
Chief Operating Officer
Total Annual Compensation: $6.6K
Compensation as of Fiscal Year 2013.

biostar pharmaceuticals inc (BSPM) Key Developments

Biostar Pharmaceuticals Signs on Joint Research and Development Agreement with Northwest University

Biostar Pharmaceuticals, Inc. has signed a joint research and development agreement with Northwest University. The agreement has been signed for further development of Danshensu Yibingzhi, a Class One drug for treatment of cardiovascular diseases. Danshensu Yibingzhi was developed by Professor Xiaohui Zheng and his research team after 14 years of research, and was recently approved by the Education Department of Shaanxi Province and The Finance Department of Shaanxi Province for the further industrialization and marketing.

Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014

Biostar Pharmaceuticals, Inc. reported unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company’s sales, net were $14,651,054 against $15,009,432 a year ago. Income from operations was $183,437 against $745,982 a year ago. Income before income tax was $486,928 against $996,522 a year ago. Net income was $239,567 or $0.02 per basic and diluted share against $387,817 or $0.03 per basic and diluted share a year ago. For the nine months, the company’s sales, net were $47,031,072 against $41,752,195 a year ago. Loss from operations was $124,327 against income of $681,353 a year ago. Income before income tax was $2,271,684 against $1,521,856 a year ago. Net income was $2,191,731 or $0.15 per basic and diluted share against $216,800 or $0.02 per basic and diluted share a year ago. Net cash used in operating activities was $544,443 against net cash from operations was $13,708,009 a year ago. Purchase of property, plant and equipment was $484,778 against $978,377 a year ago.

Biostar Pharmaceuticals, Inc., Annual General Meeting, Dec 03, 2014

Biostar Pharmaceuticals, Inc., Annual General Meeting, Dec 03, 2014., at 09:00 China Standard Time. Location: at the company's offices at No. 588 Shiji Xi Avenue. Agenda: To elect directors, each to serve until the next annual meeting of shareholders or until each successor is duly elected and qualified; to ratify the appointment of Mazars CPA Limited as the company’s independent registered public accounting firm for the year ending December 31, 2014; to approve the 2014 Equity Incentive Plan; and to transact any other business that is properly brought before the annual meeting or any adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSPM:US $1.18 USD 0.00

BSPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSPM.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSPM Industry Range
Price/Earnings 6.7x
Price/Sales 0.3x
Price/Book 0.3x
Price/Cash Flow 6.6x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSTAR PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at